T. Rowe Price Associates’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-28,305
| Closed | -$28K | – | 2948 |
|
|
2023
Q2 | $28K | Hold |
28,305
| – | – | ﹤0.01% | 2854 |
|
|
2023
Q1 | $22K | Sell |
28,305
-6,446
| -19% | -$4.7K | ﹤0.01% | 2854 |
|
|
2022
Q4 | $13K | Sell |
34,751
-601
| -2% | -$253 | ﹤0.01% | 2896 |
|
|
2022
Q3 | $16K | Sell |
35,352
-5,596
| -14% | -$5.5K | ﹤0.01% | 2920 |
|
|
2022
Q2 | $32K | Sell |
40,948
-14,078
| -26% | -$12.4K | ﹤0.01% | 2906 |
|
|
2022
Q1 | $71K | Buy |
55,026
+6,375
| +13% | +$5.87K | ﹤0.01% | 2892 |
|
|
2021
Q4 | $62K | Sell |
48,651
-60,253
| -55% | -$108K | ﹤0.01% | 2914 |
|
|
2021
Q3 | $237K | Sell |
108,904
-21,200
| -16% | -$57.9K | ﹤0.01% | 2659 |
|
|
2021
Q2 | $488K | Buy |
130,104
+4,412
| +4% | +$15.3K | ﹤0.01% | 2403 |
|
|
2021
Q1 | $410K | Buy |
125,692
+2,441
| +2% | +$8.75K | ﹤0.01% | 2457 |
|
|
2020
Q4 | $420K | Sell |
123,251
-6,397
| -5% | -$26.3K | ﹤0.01% | 2311 |
|
|
2020
Q3 | $529K | Sell |
129,648
-10,299
| -7% | -$39.2K | ﹤0.01% | 2074 |
|
|
2020
Q2 | $473K | Buy |
139,947
+5,309
| +4% | +$15.5K | ﹤0.01% | 2068 |
|
|
2020
Q1 | $314K | Buy |
134,638
+81,111
| +152% | +$222K | ﹤0.01% | 2172 |
|
|
2019
Q4 | $195K | Buy |
53,527
+119
| +0.2% | +$961 | ﹤0.01% | 2409 |
|
|
2019
Q3 | $443K | Buy |
53,408
+1,617
| +3% | +$13.1K | ﹤0.01% | 2144 |
|
|
2019
Q2 | $446K | Buy |
51,791
+486
| +0.9% | +$4.35K | ﹤0.01% | 2150 |
|
|
2019
Q1 | $548K | Buy |
51,305
+631
| +1% | +$6.76K | ﹤0.01% | 2081 |
|
|
2018
Q4 | $443K | Buy |
50,674
+28,671
| +130% | +$365K | ﹤0.01% | 2122 |
|
|
2018
Q3 | $370K | Buy |
22,003
+703
| +3% | +$15.2K | ﹤0.01% | 2272 |
|
|
2018
Q2 | $446K | Buy |
21,300
+3,285
| +18% | +$60.9K | ﹤0.01% | 2184 |
|
|
2018
Q1 | $290K | Buy |
18,015
+329
| +2% | +$6.52K | ﹤0.01% | 2306 |
|
|
2017
Q4 | $335K | Sell |
17,686
-8,330
| -32% | -$151K | ﹤0.01% | 2241 |
|
|
2017
Q3 | $366K | Hold |
26,016
| – | – | ﹤0.01% | 2208 |
|
|
2017
Q2 | $194K | Sell |
26,016
-1,184
| -4% | -$7.74K | ﹤0.01% | 2392 |
|
|
2017
Q1 | $177K | Hold |
27,200
| – | – | ﹤0.01% | 2420 |
|
|
2016
Q4 | $120K | Hold |
27,200
| – | – | ﹤0.01% | 2455 |
|
|
2016
Q3 | $127K | Hold |
27,200
| – | – | ﹤0.01% | 2415 |
|
|
2016
Q2 | $179K | Hold |
27,200
| – | – | ﹤0.01% | 2354 |
|
|
2016
Q1 | $173K | Hold |
27,200
| – | – | ﹤0.01% | 2318 |
|
|
2015
Q4 | $164K | Buy |
+27,200
| New | +$156K | ﹤0.01% | 2344 |
|
T. Rowe Price Associates's SPPI Position: Q3 2023 in Review
T. Rowe Price Associates sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2023, closing a stake of 28,305 shares — an estimated $28K sold.
T. Rowe Price Associates first reported a position in SPPI in Q4 2015 and held it in 31 quarters. The position peaked at $548K in Q1 2019. 0 funds tracked by Wall St. Rank hold SPPI as of Q3 2023.
- T. Rowe Price Associates reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2023 after selling out during the quarter.
- T. Rowe Price Associates sold 28,305 Spectrum Pharmaceuticals Inc shares in Q3 2023, an estimated $28K.
- T. Rowe Price Associates first reported a position in Spectrum Pharmaceuticals Inc in Q4 2015 and held it in 31 quarters.
- T. Rowe Price Associates's Spectrum Pharmaceuticals Inc position peaked at $548K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2023.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.